Dow Jones Newswires: WuXi XDC sets its Hong Kong IPO price at high end of range
A unit of Chinese contract drugmaker Wuxi Biologics set its initial public offering price at the top end of its guided range, indicating strong demand in a choppy year for listings in Hong Kong.